Related Experiment Video
Updated: May 9, 2025

Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation
Published on: March 14, 2017
Combination Treatment With Intravenous and Oral Calcimimetics for Secondary Hyperparathyroidism in Hemodialysis
Ryoichi Nakazawa1, Akira Onozaki1, Kazuhiro Akiyama2
1Department of Nephrology, Tokatsu Clinic Hospital, Matsudo, JPN.
Background And Aim:
Secondary hyperparathyroidism (SHPT) is a common and serious complication in patients on hemodialysis (HD), leading to significant morbidity and mortality. Parathyroidectomy (PTx) is an established treatment for refractory SHPT, but many patients refuse this surgical option. This study evaluates the efficacy of combination treatment using intravenous and oral calcimimetics in managing SHPT in patients who decline PTx. This study aimed to assess the impact of combination calcimimetic treatment on plasma parathyroid hormone (PTH) levels, mineral metabolism, and clinical outcomes in patients on hemodialysis with SHPT who refuse PTx.
Methods:
This retrospective study involved seven patients on HD with refractory SHPT who declined PTX. They were treated with various combinations of intravenous (etelcalcetide or upacicalcet), oral (cinacalcet or evocalcet) calcimimetics, and vitamin D receptor activators (VDRAs), with or without denosumab. Clinical outcomes, including changes in plasma PTH levels, mineral metabolism, and adverse events, were monitored over a period ranging from 10 to 100 months.
Results:
Combination treatment significantly reduced plasma PTH levels in all patients (median reduction from 379 pg/mL to 193 pg/mL). No gastrointestinal complications were reported, confirming the tolerability of the regimen. However, two patients developed renal cancer, and one patient died from cardiovascular disease, highlighting the complex comorbidities in this population. These findings underscore the effectiveness of combination calcimimetics in managing SHPT in patients who refuse surgery, although careful monitoring for adverse events is necessary.
Conclusion:
The combination of intravenous and oral calcimimetics is an effective therapeutic option for managing SHPT in patients on HD who refuse PTX. While promising, the long-term safety and potential risks of this approach, including the occurrence of malignancies, warrant further investigation in larger prospective studies.
Related Concept Videos
Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Skeleton and Calcium Homeostasis
Heart Failure Drugs: Diuretics
Antihypertensive Drugs: Potassium-Sparing Diuretics
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

